



## Clinical trial results:

### A Double-Blind, Randomized, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of PF 00547659 in Subjects With Crohn's Disease (OPERA)

#### Summary

EudraCT number	2010-023437-30
Trial protocol	SK BE SE AT DE PT NO NL ES PL BG
Global end of trial date	09 October 2015

#### Results information

Result version number	v1 (current)
This version publication date	24 October 2016
First version publication date	24 October 2016

#### Trial information

##### Trial identification

Sponsor protocol code	A7281006
-----------------------	----------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01276509
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Pfizer, Inc
Sponsor organisation address	235 E 42nd Street, New York, United States, 10017
Public contact	Call Center, ClinicalTrial.gov, 1 667181021, ClinicalTrials.gov.inquiries@pfizer.com
Scientific contact	Call Center, ClinicalTrial.gov, 1 667181021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	09 October 2015
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	09 October 2015
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

To determine the number of subjects that experienced a decrease in Crohn's Disease Activity Index (CDAI) of at least 70 points by the Week 8 or Week 12 assessment.

Protection of trial subjects:

This study was conducted in compliance with the ethical principles originating in or derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. In addition, all local regulatory requirements were followed, in particular, those affording greater protection to the safety of trial subjects.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	06 April 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Belgium: 16
Country: Number of subjects enrolled	Austria: 5
Country: Number of subjects enrolled	Canada: 7
Country: Number of subjects enrolled	France: 18
Country: Number of subjects enrolled	Germany: 26
Country: Number of subjects enrolled	Japan: 8
Country: Number of subjects enrolled	Korea, Republic of: 12
Country: Number of subjects enrolled	Netherlands: 29
Country: Number of subjects enrolled	Norway: 5
Country: Number of subjects enrolled	Serbia: 14
Country: Number of subjects enrolled	Slovakia: 9
Country: Number of subjects enrolled	South Africa: 4
Country: Number of subjects enrolled	Spain: 12
Country: Number of subjects enrolled	United States: 82
Country: Number of subjects enrolled	Poland: 15
Worldwide total number of subjects	262
EEA total number of subjects	135

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	259
From 65 to 84 years	3
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

The study was conducted at 103 centers in Austria (1), Bulgaria (2), Belgium (3), Canada (3), France (8), Germany (8), Japan (7), Korea (7), Netherlands (3), Norway (3), Poland (4), Serbia (4), Slovakia (4), South Africa (3), Spain (6), and the US (37). Male and/or female subjects between the ages of 18 and 75 years were included in the study.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Subject

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	PF-00547659 22.5 mg

Arm description:

PF-00547659 22.5 mg delivered subcutaneously (SC), 3 doses separated by 4 weeks.

Arm type	Experimental
Investigational medicinal product name	PF-00547659
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

PF-00547659 22.5 mg delivered subcutaneously (SC), 3 doses separated by 4 weeks.

<b>Arm title</b>	PF-00547659 75 mg
------------------	-------------------

Arm description:

PF-00547659 75 mg delivered SC, 3 doses separated by 4 weeks.

Arm type	Experimental
Investigational medicinal product name	PF-00547659
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

PF-00547659 75 mg delivered SC, 3 doses separated by 4 weeks.

<b>Arm title</b>	PF-00547659 225 mg
------------------	--------------------

Arm description:

PF-00547659 225 mg delivered SC, 3 doses separated by 4 weeks.

Arm type	Experimental
Investigational medicinal product name	PF-00547659
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

PF-00547659 225 mg delivered SC, 3 doses separated by 4 weeks.

<b>Arm title</b>	Placebo
Arm description:	
Placebo delivered SC, 3 doses separated by 4 weeks.	
Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Matching placebo delivered SC, 3 doses separated by 4 weeks.

<b>Number of subjects in period 1</b>	PF-00547659 22.5 mg	PF-00547659 75 mg	PF-00547659 225 mg
Started	66	65	68
Completed	53	53	63
Not completed	13	12	5
Consent withdrawn by subject	1	2	-
Adverse event, non-fatal	9	8	4
Pregnancy	1	-	-
Unspecified	-	1	-
Lack of efficacy	2	1	1

<b>Number of subjects in period 1</b>	Placebo
Started	63
Completed	58
Not completed	5
Consent withdrawn by subject	-
Adverse event, non-fatal	3
Pregnancy	-
Unspecified	-
Lack of efficacy	2

## Baseline characteristics

### Reporting groups

Reporting group title	PF-00547659 22.5 mg
Reporting group description: PF-00547659 22.5 mg delivered subcutaneously (SC), 3 doses separated by 4 weeks.	
Reporting group title	PF-00547659 75 mg
Reporting group description: PF-00547659 75 mg delivered SC, 3 doses separated by 4 weeks.	
Reporting group title	PF-00547659 225 mg
Reporting group description: PF-00547659 225 mg delivered SC, 3 doses separated by 4 weeks.	
Reporting group title	Placebo
Reporting group description: Placebo delivered SC, 3 doses separated by 4 weeks.	

Reporting group values	PF-00547659 22.5 mg	PF-00547659 75 mg	PF-00547659 225 mg
Number of subjects	66	65	68
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	64	65	68
From 65-84 years	2	0	0
85 years and over	0	0	0
Age Continuous Units: years			
arithmetic mean	37.3	34.4	35.9
standard deviation	± 13	± 10.7	± 11
Gender, Male/Female Units: Participants			
FEMALE	48	35	43
MALE	18	30	25

Reporting group values	Placebo	Total	
Number of subjects	63	262	
Age categorical Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	

Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	62	259	
From 65-84 years	1	3	
85 years and over	0	0	
Age Continuous			
Units: years			
arithmetic mean	34.4		
standard deviation	± 11.1	-	
Gender, Male/Female			
Units: Participants			
FEMALE	30	156	
MALE	33	106	

## End points

### End points reporting groups

Reporting group title	PF-00547659 22.5 mg
Reporting group description: PF-00547659 22.5 mg delivered subcutaneously (SC), 3 doses separated by 4 weeks.	
Reporting group title	PF-00547659 75 mg
Reporting group description: PF-00547659 75 mg delivered SC, 3 doses separated by 4 weeks.	
Reporting group title	PF-00547659 225 mg
Reporting group description: PF-00547659 225 mg delivered SC, 3 doses separated by 4 weeks.	
Reporting group title	Placebo
Reporting group description: Placebo delivered SC, 3 doses separated by 4 weeks.	

### Primary: Percentage of Subjects With Crohn's Disease Activity Index (CDAI) Response Rate

End point title	Percentage of Subjects With Crohn's Disease Activity Index (CDAI) Response Rate
End point description: Crohn's Disease Activity Index (CDAI) 70 response rate at week 8 or week 12 (between the investigational product group and the placebo group). The full analysis set included all randomized subjects who received at least one dose of study medication.	
End point type	Primary
End point timeframe: Week 8 and week 12	

End point values	PF-00547659 22.5 mg	PF-00547659 75 mg	PF-00547659 225 mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	66	65	68	63
Units: Percentage of Subjects				
number (not applicable)				
Week 8 (n = 50, 55, 62, 56)	52.7	60.1	62.7	47.7
Week 12 (n = 51, 49, 61, 54)	62	64.7	57.5	58.6

### Statistical analyses

Statistical analysis title	Difference from placebo at Week 8
Statistical analysis description: The full analysis set included all randomized subjects who received at least one dose of study medication.	
Comparison groups	PF-00547659 22.5 mg v Placebo



Number of subjects included in analysis	129
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.3393
Method	Mixed models analysis
Parameter estimate	Difference in Percentage
Point estimate	0.05
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.149
upper limit	0.249
Variability estimate	Standard error of the mean
Dispersion value	0.121

<b>Statistical analysis title</b>	Difference from placebo at Week 8
-----------------------------------	-----------------------------------

Statistical analysis description:

The full analysis set included all randomized subjects who received at least one dose of study medication.

Comparison groups	PF-00547659 75 mg v Placebo
Number of subjects included in analysis	128
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.1433
Method	Mixed models analysis
Parameter estimate	Difference in Percentage
Point estimate	0.124
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.068
upper limit	0.316
Variability estimate	Standard error of the mean
Dispersion value	0.117

<b>Statistical analysis title</b>	Difference from placebo at Week 8
-----------------------------------	-----------------------------------

Statistical analysis description:

The full analysis set included all randomized subjects who received at least one dose of study medication.

Comparison groups	PF-00547659 225 mg v Placebo
Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.0922
Method	Mixed models analysis
Parameter estimate	Difference in Percentage
Point estimate	0.15

Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.036
upper limit	0.335
Variability estimate	Standard error of the mean
Dispersion value	0.113

<b>Statistical analysis title</b>	Difference from placebo at Week 12
-----------------------------------	------------------------------------

Statistical analysis description:

The full analysis set included all randomized subjects who received at least one dose of study medication.

Comparison groups	PF-00547659 22.5 mg v Placebo
Number of subjects included in analysis	129
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.3864
Method	Mixed models analysis
Parameter estimate	Difference in Percentage
Point estimate	0.034
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.158
upper limit	0.225
Variability estimate	Standard error of the mean
Dispersion value	0.117

<b>Statistical analysis title</b>	Difference from placebo at Week 12
-----------------------------------	------------------------------------

Statistical analysis description:

The full analysis set included all randomized subjects who received at least one dose of study medication.

Comparison groups	PF-00547659 75 mg v Placebo
Number of subjects included in analysis	128
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.3005
Method	Mixed models analysis
Parameter estimate	Difference in Percentage
Point estimate	0.061
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.131
upper limit	0.253
Variability estimate	Standard error of the mean
Dispersion value	0.117

<b>Statistical analysis title</b>	Difference from placebo at Week 12
Statistical analysis description: The full analysis set included all randomized subjects who received at least one dose of study medication.	
Comparison groups	PF-00547659 225 mg v Placebo
Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.5385
Method	Mixed models analysis
Parameter estimate	Difference in Percentage
Point estimate	-0.011
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.198
upper limit	0.176
Variability estimate	Standard error of the mean
Dispersion value	0.114

## Secondary: Safety and Tolerability of PF00547659 Dose Levels versus Placebo

End point title	Safety and Tolerability of PF00547659 Dose Levels versus Placebo
End point description: Number of subjects with adverse events (AEs), withdrawals due to AEs and Serious AEs (SAEs) were reported by all causalities and treatment related. The safety analysis set included all subjects who received at least 1 dose of study medication.	
End point type	Secondary
End point timeframe: Week 1 up to Week 12	

End point values	PF-00547659 22.5 mg	PF-00547659 75 mg	PF-00547659 225 mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	66	65	68	63
Units: Subjects				
Number of AEs (all causalities)	175	192	190	141
Number of AEs (treatment related)	40	55	64	40
Subjects with AEs (all causalities)	57	51	54	54
Subjects with AEs (treatment related)	20	24	29	22
Withdrawal due to AEs (all causalities)	9	8	4	3
Withdrawal due to AEs (treatment related)	5	2	0	1
Subjects with SAEs (all causalities)	11	9	11	5

Subjects with SAEs (treatment related)	4	4	2	2
--	---	---	---	---

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Subjects with a Crohn's Disease Activity Index (CDAI) Remission

End point title	Percentage of Subjects with a Crohn's Disease Activity Index (CDAI) Remission
End point description: Percentage of subjects with a CDAI remission (defined as a CDAI reduction to <150 points). The full analysis set included all randomized subjects who received at least one dose of study medication.	
End point type	Secondary
End point timeframe: Weeks 8 and week 12	

End point values	PF-00547659 22.5 mg	PF-00547659 75 mg	PF-00547659 225 mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	66	65	68	63
Units: Percentage of subjects				
number (not applicable)				
Week 8 (n = 50, 56, 62, 57)	29.1	23.8	26.9	16.7
Week 12 (n= 51, 49, 61, 55)	26.8	28.5	29.6	23

## Statistical analyses

Statistical analysis title	Difference from placebo at week 8
Statistical analysis description: The full analysis set included all randomized subjects who received at least one dose of study medication.	
Comparison groups	PF-00547659 22.5 mg v Placebo
Number of subjects included in analysis	129
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.1234
Method	Mixed models analysis
Parameter estimate	Difference in Percentage
Point estimate	0.124

Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.052
upper limit	0.299
Variability estimate	Standard error of the mean
Dispersion value	0.107

<b>Statistical analysis title</b>	Difference from placebo at week 8
-----------------------------------	-----------------------------------

Statistical analysis description:

The full analysis set included all randomized subjects who received at least one dose of study medication.

Comparison groups	PF-00547659 75 mg v Placebo
Number of subjects included in analysis	128
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.2378
Method	Mixed models analysis
Parameter estimate	Difference in Percentage
Point estimate	0.071
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.092
upper limit	0.234
Variability estimate	Standard error of the mean
Dispersion value	0.099

<b>Statistical analysis title</b>	Difference from placebo at week 8
-----------------------------------	-----------------------------------

Statistical analysis description:

The full analysis set included all randomized subjects who received at least one dose of study medication.

Comparison groups	PF-00547659 225 mg v Placebo
Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.1529
Method	Mixed models analysis
Parameter estimate	Difference in Percentage
Point estimate	0.102
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.062
upper limit	0.266
Variability estimate	Standard error of the mean
Dispersion value	0.1

<b>Statistical analysis title</b>	Difference from placebo at week 12
Statistical analysis description: The full analysis set included all randomized subjects who received at least one dose of study medication.	
Comparison groups	PF-00547659 22.5 mg v Placebo
Number of subjects included in analysis	129
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.3661
Method	Mixed models analysis
Parameter estimate	Difference in Percentage
Point estimate	0.038
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.146
upper limit	0.222
Variability estimate	Standard error of the mean
Dispersion value	0.112

<b>Statistical analysis title</b>	Difference from placebo at week 12
Statistical analysis description: The full analysis set included all randomized subjects who received at least one dose of study medication.	
Comparison groups	PF-00547659 75 mg v Placebo
Number of subjects included in analysis	128
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.3169
Method	Mixed models analysis
Parameter estimate	Difference in Percentage
Point estimate	0.055
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.136
upper limit	0.246
Variability estimate	Standard error of the mean
Dispersion value	0.116

<b>Statistical analysis title</b>	Difference from placebo at week 12
Statistical analysis description: The full analysis set included all randomized subjects who received at least one dose of study medication.	

Comparison groups	PF-00547659 225 mg v Placebo
Number of subjects included in analysis	131
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.2755
Method	Mixed models analysis
Parameter estimate	Difference in Percentage
Point estimate	0.066
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.116
upper limit	0.248
Variability estimate	Standard error of the mean
Dispersion value	0.111

### Secondary: Crohn's Disease Activity Index (CDAI)-70 Response Rates Over Time

End point title	Crohn's Disease Activity Index (CDAI)-70 Response Rates Over Time
End point description:	
Percentage of subjects with Crohn's Disease Activity Index (CDAI)-70 response were reported. The full analysis set included all randomized subjects who received at least one dose of study medication.	
End point type	Secondary
End point timeframe:	
Week 2, 4, 6, 8, 10 and 12	

End point values	PF-00547659 22.5 mg	PF-00547659 75 mg	PF-00547659 225 mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	66	65	68	63
Units: Percentage of subjects				
number (confidence interval 90%)				
Week 2 (n = 64, 60, 63, 60)	35.1 (22.8 to 49.6)	22.4 (12.9 to 36)	33.8 (21.6 to 48.5)	35.5 (22.9 to 50.5)
Week 4 (n = 58, 60, 65, 58)	38 (24.9 to 53.2)	39.5 (26.3 to 54.4)	36.2 (23.7 to 51)	38.3 (25.1 to 53.5)
Week 6 (n =56, 54, 64, 58)	45.3 (31.1 to 60.3)	53.4 (38.2 to 67.9)	47.5 (33.3 to 62.1)	48 (33.5 to 62.9)
Week 8 (n =50, 55, 62, 56)	52.7 (37.2 to 67.7)	60.1 (44.9 to 73.6)	62.7 (47.9 to 75.4)	47.7 (33.1 to 62.7)
Week 10 (n =50, 48, 60, 52)	67.4 (52 to 79.7)	58.2 (42.3 to 72.6)	61.6 (46.8 to 74.6)	53 (37.6 to 67.8)
Week 12 (n = 51, 49, 61, 54)	62 (46.5 to 75.3)	64.7 (48.9 to 77.8)	57.5 (42.6 to 71.2)	58.6 (43.3 to 72.4)

### Statistical analyses

No statistical analyses for this end point

### Secondary: Crohn's Disease Activity Index (CDAI) -100 Response Rates Over Timer

End point title	Crohn's Disease Activity Index (CDAI) -100 Response Rates Over Timer
End point description: Percentage of subjects with Crohn's Disease Activity Index (CDAI)-100 response were reported. The full analysis set included all randomized subjects who received at least one dose of study medication.	
End point type	Secondary
End point timeframe: Week 2, 4, 6, 8, 10 and 12	

End point values	PF-00547659 22.5 mg	PF-00547659 75 mg	PF-00547659 225 mg	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	66	65	68	63
Units: Percentage of subjects				
number (confidence interval 90%)				
Week 2 (n = 64, 60, 63, 60)	19.3 (10.6 to 32.6)	18.4 (9.9 to 31.7)	20 (11 to 33.6)	18.5 (9.9 to 31.9)
Week 4 (n = 58, 60 ,65, 58)	29.2 (17.5 to 44.6)	32.3 (20 to 47.5)	28.2 (17 to 43)	29.5 (17.7 to 44.9)
Week 6 (n =56, 54, 64, 58)	40.6 (26.6 to 56.4)	42.6 (28.2 to 58.5)	40.4 (26.8 to 55.8)	39.3 (25.5 to 55)
Week 8 (n = 50, 55, 62, 56)	50.5 (34.8 to 66.2)	48.3 (33.3 to 63.7)	57 (41.8 to 71)	41.4 (27.2 to 57.3)
Week 10 (n = 50, 48, 62, 52)	53.2 (37.3 to 68.5)	47.4 (31.8 to 63.5)	50.9 (35.9 to 65.7)	43.6 (28.7 to 59.7)
Week 12 (n = 51, 49, 61, 54)	56 (40.1 to 70.7)	47.7 (32.2 to 63.7)	53.8 (38.7 to 68.4)	44.4 (29.6 to 60.2)

### Statistical analyses

No statistical analyses for this end point

### Secondary: Immunogenicity Assessment of Anti-drug Antibodies (ADAs)

End point title	Immunogenicity Assessment of Anti-drug Antibodies (ADAs) <sup>[1]</sup>
End point description: Confirmed cumulative incidence of anti drug antibodies development to PF-00547659. The safety analysis set included all subjects who received at least 1 dose of PF-00547659. Subjects in placebo arm were not included in this analysis.	
End point type	Secondary
End point timeframe: Day 1, Week 4, Week 8, Week 12, Week 20, Week 28, Week 36	

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The 4th arm is placebo control. Hence, PK evaluations were not done.



End point values	PF-00547659 22.5 mg	PF-00547659 75 mg	PF-00547659 225 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	66	65	68	
Units: Number of event				
Day 1 (n = 46, 52, 53)	3	5	1	
Week 4 (n = 55, 52, 55)	2	4	2	
Week 8 (n = 44, 47, 56)	1	1	1	
Week 12 (n = 47, 51, 51)	3	5	1	
Week 20 (n = 4, 3, 1)	0	0	0	
Week 28 (n = 8, 1, 1)	1	0	0	
Week 36 (n = 6, 2, 1)	0	0	0	

## Statistical analyses

No statistical analyses for this end point

## Secondary: The Pharmacokinetics (PK) of Total PF-00547659 - Area under the Concentration Time Profile from Time Zero Extrapolated to Infinite Time (AUCinf)

End point title	The Pharmacokinetics (PK) of Total PF-00547659 - Area under the Concentration Time Profile from Time Zero Extrapolated to Infinite Time (AUCinf) <sup>[2]</sup>
-----------------	---

End point description:

The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to area under the concentration-time profile (AUC), clearance (CL) and half life were estimated using data pooled from both typical and additional PK groups. AUCinf is area under the concentration time profile from time zero extrapolated to infinite time. All subjects who received at least 1 dose of investigational product and had data for at least 1 PK concentration were included in the PK concentration analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1, 14, 28, 42, 56, 70, 84, 112, 140, 168, 196, 224 and 252

Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The 4th arm is placebo control. Hence, PK evaluations were not done.

End point values	PF-00547659 22.5 mg	PF-00547659 75 mg	PF-00547659 225 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	6	8	6	
Units: µg•hr/mL				
geometric mean (geometric coefficient of variation)	615300 (± 63)	4464000 (± 28)	13760000 (± 49)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: The Pharmacokinetics (PK) of Total PF-00547659 - Area under the

## Concentration Time Profile from Time Zero to Time Tau (AUCtau)

End point title	The Pharmacokinetics (PK) of Total PF-00547659 - Area under the Concentration Time Profile from Time Zero to Time Tau (AUCtau) <sup>[3]</sup>
-----------------	---

### End point description:

The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. AUCtau is area under the concentration time profile from time zero to time tau, the dosing interval, where tau = 672 hours (4 weeks). All subjects who received at least 1 dose of investigational product and had data for at least 1 PK concentration were included in the PK concentration analysis.

End point type	Secondary
----------------	-----------

### End point timeframe:

Day 1, 14, 28, 42, 56, 70, 84, 112, 140, 168, 196, 224 and 252

### Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The 4th arm is placebo control. Hence, PK evaluations were not done.

End point values	PF-00547659 22.5 mg	PF-00547659 75 mg	PF-00547659 225 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	7	10	12	
Units: µg•hr/mL				
geometric mean (geometric coefficient of variation)	549500 (± 53)	4214000 (± 31)	10850000 (± 45)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: The Pharmacokinetics (PK) of Total PF-00547659 - Maximum Observed Concentration (Cmax)

End point title	The Pharmacokinetics (PK) of Total PF-00547659 - Maximum Observed Concentration (Cmax) <sup>[4]</sup>
-----------------	---

### End point description:

The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. Cmax is maximum observed concentration. All subjects who received at least 1 dose of investigational product and had data for at least 1 PK concentration were included in the PK concentration analysis.

End point type	Secondary
----------------	-----------

### End point timeframe:

Day 1, 14, 28, 42, 56, 70, 84, 112, 140, 168, 196, 224 and 252

### Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The 4th arm is placebo control. Hence, PK evaluations were not done.

End point values	PF-00547659 22.5 mg	PF-00547659 75 mg	PF-00547659 225 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	7	10	13	
Units: µg/mL				
geometric mean (geometric coefficient of variation)	1756 (± 45)	10800 (± 22)	24100 (± 47)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: The Pharmacokinetics (PK) of Total PF-00547659 - Time for Cmax (Tmax)

End point title	The Pharmacokinetics (PK) of Total PF-00547659 - Time for Cmax (Tmax) <sup>[5]</sup>
-----------------	--

End point description:

The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. Tmax is time for Cmax. All subjects who received at least 1 dose of investigational product and had data for at least 1 PK concentration were included in the PK concentration analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1, 14, 28, 42, 56, 70, 84, 112, 140, 168, 196, 224 and 252

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The 4th arm is placebo control. Hence, PK evaluations were not done.

End point values	PF-00547659 22.5 mg	PF-00547659 75 mg	PF-00547659 225 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	7	10	13	
Units: Hours				
median (full range (min-max))	140 (43.9 to 333)	143 (44.9 to 171)	165 (51.7 to 214)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: The Pharmacokinetics (PK) of Total PF-00547659 - Terminal Half Life (Thalf)

End point title	The Pharmacokinetics (PK) of Total PF-00547659 - Terminal Half Life (Thalf) <sup>[6]</sup>
-----------------	--

End point description:

The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. Thalf is terminal half life. All subjects who received at least 1 dose of investigational product and had data for at least 1 PK concentration were included in the PK concentration analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1, 14, 28, 42, 56, 70, 84, 112, 140, 168, 196, 224 and 252

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The 4th arm is placebo control. Hence, PK evaluations were not done.

<b>End point values</b>	PF-00547659 22.5 mg	PF-00547659 75 mg	PF-00547659 225 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	6	8	6	
Units: Day				
arithmetic mean (standard deviation)	4.977 (± 2.8435)	8.77 (± 2.3571)	12.22 (± 3.8306)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: The Pharmacokinetics (PK) of Total PF-00547659 - Apparent Clearance (CL/F)

End point title	The Pharmacokinetics (PK) of Total PF-00547659 - Apparent Clearance (CL/F) <sup>[7]</sup>
-----------------	---

End point description:

The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. CL/F is apparent clearance. All subjects who received at least 1 dose of investigational product and had data for at least 1 PK concentration were included in the PK concentration analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1, 14, 28, 42, 56, 70, 84, 112, 140, 168, 196, 224 and 252

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The 4th arm is placebo control. Hence, PK evaluations were not done.

<b>End point values</b>	PF-00547659 22.5 mg	PF-00547659 75 mg	PF-00547659 225 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	6	8	6	
Units: mL/hr				
geometric mean (geometric coefficient of variation)	36.54 (± 63)	16.79 (± 28)	16.38 (± 49)	

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Screening to Week 36

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	18.1
--------------------	------

### Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Placebo delivered SC, 3 doses separated by 4 weeks.

Reporting group title	PF-00547659 225 mg
-----------------------	--------------------

Reporting group description:

PF-00547659 225 mg delivered SC, 3 doses separated by 4 weeks.

Reporting group title	PF-00547659 75 mg
-----------------------	-------------------

Reporting group description:

PF-00547659 75 mg delivered SC, 3 doses separated by 4 weeks.

Reporting group title	PF-00547659 22.5 mg
-----------------------	---------------------

Reporting group description:

PF-00547659 22.5 mg delivered subcutaneously (SC), 3 doses separated by 4 weeks.

Serious adverse events	Placebo	PF-00547659 225 mg	PF-00547659 75 mg
Total subjects affected by serious adverse events			
subjects affected / exposed	6 / 63 (9.52%)	11 / 68 (16.18%)	11 / 65 (16.92%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Injury, poisoning and procedural complications			
Gastrointestinal stoma complication			
subjects affected / exposed	0 / 63 (0.00%)	0 / 68 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebellar infarction			
subjects affected / exposed	0 / 63 (0.00%)	0 / 68 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			

subjects affected / exposed	0 / 63 (0.00%)	1 / 68 (1.47%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	0 / 63 (0.00%)	1 / 68 (1.47%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	0 / 63 (0.00%)	0 / 68 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	1 / 63 (1.59%)	1 / 68 (1.47%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	1 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal adhesions			
subjects affected / exposed	0 / 63 (0.00%)	1 / 68 (1.47%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis ulcerative			
subjects affected / exposed	0 / 63 (0.00%)	1 / 68 (1.47%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Crohn's disease			
subjects affected / exposed	4 / 63 (6.35%)	4 / 68 (5.88%)	6 / 65 (9.23%)
occurrences causally related to treatment / all	1 / 5	0 / 5	1 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fistula of small intestine			
subjects affected / exposed	0 / 63 (0.00%)	0 / 68 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Gastrointestinal inflammation			
subjects affected / exposed	0 / 63 (0.00%)	0 / 68 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 63 (0.00%)	0 / 68 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal stenosis			
subjects affected / exposed	1 / 63 (1.59%)	0 / 68 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	0 / 63 (0.00%)	2 / 68 (2.94%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subileus			
subjects affected / exposed	0 / 63 (0.00%)	0 / 68 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	0 / 63 (0.00%)	0 / 68 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Lung disorder			
subjects affected / exposed	0 / 63 (0.00%)	1 / 68 (1.47%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Calculus urinary			

subjects affected / exposed	0 / 63 (0.00%)	1 / 68 (1.47%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Musculoskeletal and connective tissue disorders</b>			
Arthritis			
subjects affected / exposed	0 / 63 (0.00%)	0 / 68 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myalgia			
subjects affected / exposed	0 / 63 (0.00%)	0 / 68 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Infections and infestations</b>			
Anal abscess			
subjects affected / exposed	1 / 63 (1.59%)	1 / 68 (1.47%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	0 / 63 (0.00%)	0 / 68 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver abscess			
subjects affected / exposed	0 / 63 (0.00%)	0 / 68 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative wound infection			
subjects affected / exposed	0 / 63 (0.00%)	1 / 68 (1.47%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal abscess			
subjects affected / exposed	0 / 63 (0.00%)	0 / 68 (0.00%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0



Sepsis			
subjects affected / exposed	0 / 63 (0.00%)	0 / 68 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal infection			
subjects affected / exposed	0 / 63 (0.00%)	0 / 68 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal sepsis			
subjects affected / exposed	0 / 63 (0.00%)	0 / 68 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 63 (0.00%)	1 / 68 (1.47%)	0 / 65 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 63 (0.00%)	0 / 68 (0.00%)	1 / 65 (1.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	PF-00547659 22.5 mg		
Total subjects affected by serious adverse events			
subjects affected / exposed	12 / 66 (18.18%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events			
Injury, poisoning and procedural complications			
Gastrointestinal stoma complication			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Cerebellar infarction			

subjects affected / exposed	0 / 66 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Headache			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Transient ischaemic attack			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	1 / 66 (1.52%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pyrexia			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Abdominal adhesions			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Colitis ulcerative			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Crohn's disease			
subjects affected / exposed	5 / 66 (7.58%)		
occurrences causally related to treatment / all	2 / 5		
deaths causally related to treatment / all	0 / 0		

Fistula of small intestine subjects affected / exposed	0 / 66 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal inflammation subjects affected / exposed	1 / 66 (1.52%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Intestinal obstruction subjects affected / exposed	0 / 66 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rectal stenosis subjects affected / exposed	0 / 66 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Small intestinal obstruction subjects affected / exposed	0 / 66 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Subileus subjects affected / exposed	1 / 66 (1.52%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders Cholecystitis subjects affected / exposed	1 / 66 (1.52%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders Lung disorder subjects affected / exposed	0 / 66 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Renal and urinary disorders			
Calculus urinary			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Arthritis			
subjects affected / exposed	1 / 66 (1.52%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Myalgia			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Anal abscess			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Appendicitis			
subjects affected / exposed	2 / 66 (3.03%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Liver abscess			
subjects affected / exposed	1 / 66 (1.52%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Postoperative wound infection			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rectal abscess			

subjects affected / exposed	1 / 66 (1.52%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Sepsis			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Staphylococcal infection			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Staphylococcal sepsis			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary tract infection			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	1 / 66 (1.52%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Placebo	PF-00547659 225 mg	PF-00547659 75 mg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	35 / 63 (55.56%)	42 / 68 (61.76%)	32 / 65 (49.23%)
Nervous system disorders			
Headache			
subjects affected / exposed	6 / 63 (9.52%)	8 / 68 (11.76%)	3 / 65 (4.62%)
occurrences (all)	8	9	4

General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	3 / 63 (4.76%)	2 / 68 (2.94%)	4 / 65 (6.15%)
occurrences (all)	3	2	4
Injection site erythema			
subjects affected / exposed	3 / 63 (4.76%)	2 / 68 (2.94%)	4 / 65 (6.15%)
occurrences (all)	4	3	8
Oedema peripheral			
subjects affected / exposed	0 / 63 (0.00%)	5 / 68 (7.35%)	1 / 65 (1.54%)
occurrences (all)	0	5	2
Pyrexia			
subjects affected / exposed	7 / 63 (11.11%)	8 / 68 (11.76%)	6 / 65 (9.23%)
occurrences (all)	8	9	8
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	3 / 63 (4.76%)	4 / 68 (5.88%)	1 / 65 (1.54%)
occurrences (all)	3	5	2
Crohn's disease			
subjects affected / exposed	5 / 63 (7.94%)	1 / 68 (1.47%)	7 / 65 (10.77%)
occurrences (all)	6	1	8
Diarrhoea			
subjects affected / exposed	1 / 63 (1.59%)	1 / 68 (1.47%)	4 / 65 (6.15%)
occurrences (all)	3	1	4
Nausea			
subjects affected / exposed	7 / 63 (11.11%)	5 / 68 (7.35%)	4 / 65 (6.15%)
occurrences (all)	7	5	5
Proctalgia			
subjects affected / exposed	0 / 63 (0.00%)	1 / 68 (1.47%)	4 / 65 (6.15%)
occurrences (all)	0	1	4
Vomiting			
subjects affected / exposed	4 / 63 (6.35%)	3 / 68 (4.41%)	3 / 65 (4.62%)
occurrences (all)	4	3	3
Skin and subcutaneous tissue disorders			
Erythema			
subjects affected / exposed	2 / 63 (3.17%)	4 / 68 (5.88%)	2 / 65 (3.08%)
occurrences (all)	2	4	3

Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	3 / 63 (4.76%)	5 / 68 (7.35%)	6 / 65 (9.23%)
occurrences (all)	3	5	6
Back pain			
subjects affected / exposed	2 / 63 (3.17%)	4 / 68 (5.88%)	1 / 65 (1.54%)
occurrences (all)	2	4	1
Infections and infestations			
Influenza			
subjects affected / exposed	1 / 63 (1.59%)	1 / 68 (1.47%)	2 / 65 (3.08%)
occurrences (all)	1	1	2
Nasopharyngitis			
subjects affected / exposed	5 / 63 (7.94%)	5 / 68 (7.35%)	4 / 65 (6.15%)
occurrences (all)	5	6	4
Urinary tract infection			
subjects affected / exposed	5 / 63 (7.94%)	3 / 68 (4.41%)	1 / 65 (1.54%)
occurrences (all)	6	4	1
Vulvovaginal mycotic infection			
subjects affected / exposed	0 / 63 (0.00%)	0 / 68 (0.00%)	0 / 65 (0.00%)
occurrences (all)	0	0	0

<b>Non-serious adverse events</b>	PF-00547659 22.5 mg		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	36 / 66 (54.55%)		
Nervous system disorders			
Headache			
subjects affected / exposed	6 / 66 (9.09%)		
occurrences (all)	6		
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	5 / 66 (7.58%)		
occurrences (all)	7		
Injection site erythema			
subjects affected / exposed	1 / 66 (1.52%)		
occurrences (all)	1		
Oedema peripheral			

subjects affected / exposed	0 / 66 (0.00%)		
occurrences (all)	0		
Pyrexia			
subjects affected / exposed	5 / 66 (7.58%)		
occurrences (all)	7		
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	7 / 66 (10.61%)		
occurrences (all)	8		
Crohn's disease			
subjects affected / exposed	5 / 66 (7.58%)		
occurrences (all)	5		
Diarrhoea			
subjects affected / exposed	1 / 66 (1.52%)		
occurrences (all)	1		
Nausea			
subjects affected / exposed	7 / 66 (10.61%)		
occurrences (all)	7		
Proctalgia			
subjects affected / exposed	1 / 66 (1.52%)		
occurrences (all)	3		
Vomiting			
subjects affected / exposed	4 / 66 (6.06%)		
occurrences (all)	5		
Skin and subcutaneous tissue disorders			
Erythema			
subjects affected / exposed	3 / 66 (4.55%)		
occurrences (all)	3		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	5 / 66 (7.58%)		
occurrences (all)	5		
Back pain			
subjects affected / exposed	0 / 66 (0.00%)		
occurrences (all)	0		
Infections and infestations			



Influenza			
subjects affected / exposed	4 / 66 (6.06%)		
occurrences (all)	4		
Nasopharyngitis			
subjects affected / exposed	3 / 66 (4.55%)		
occurrences (all)	3		
Urinary tract infection			
subjects affected / exposed	2 / 66 (3.03%)		
occurrences (all)	2		
Vulvovaginal mycotic infection			
subjects affected / exposed	3 / 66 (4.55%)		
occurrences (all)	3		

## **More information**

### **Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? No

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported